New Lung Cancer Therapy May Target Previously Untreatable Tumors

Colored x-ray of lung cancer

Lung cancer is responsible for more deaths than any other cancer. Until now, lung cancer patients with mutations in a gene called KRAS have not benefited from developments in precision therapy.

When it comes to harrowing disease diagnoses, lung cancer is a major one.

The disease is responsible for more deaths than any other cancer, exceeding 150,000 each year in the United States alone, with more than 220,000 people diagnosed annually.

Patients who have certain gene mutations greatly benefit from targeted therapies. However, patients who have tumors that test positive for mutations in the KRAS gene (pronounced “kay-rass”) currently do not respond to any targeted therapies.

Now Memorial Sloan Kettering researchers are developing ways to use a compound that targets the most common form of the KRAS mutation in lung cancer.

Drugging an “Undruggable” Target

KRAS is one of the most common mutations in lung cancer, as well as in several other cancers,” says Neal Rosen, a physician-scientist in MSK’s Molecular Pharmacology Program and Co-Chair of MSK’s Center for Mechanism-Based Therapies. “Until very recently, it was considered an ‘undruggable’ alteration.”

In a paper published in February in Science, MSK physician-scientist Piro Lito  — along with Dr. Rosen and colleagues from Wellspring Biosciences — showed how a compound called ARS853 shuts down cancer cells in cultures of lung tumors without disturbing healthy cells. The drug blocks the activity of a protein that accounts for about half of all KRAS mutations in lung cancer, called KRAS-G12C.

KRAS is one of the most common mutations in lung cancer.
Neal Rosen physician-scientist

“Because lung cancer is so widespread, drugs that directly target this protein have the potential to help thousands of people every year,” says Dr. Lito, who is a member of MSK’s Human Oncology and Pathogenesis Program and the study’s co-corresponding author.

Back to top

Stopping Cancer While Sparing Healthy Cells

“In the study, we found that ARS853 binds to the mutant KRAS protein and traps it in an inactive state,” Dr. Lito explains. “This is important because when the protein is inactivated, it stops the growth of the cancer cells and causes them to die.”

More work needs to be done before clinical trials can start. But Dr. Rosen says the findings about the function suggest that the drug will have few side effects. In addition, this research suggests the drug is a good candidate for combination therapy, in which it could be used with additional targeted therapies that block other cancer-related proteins. 

Back to top

Funding information: This research was funded by the National Institutes of Health under grants P01CA129243 and K08CA191082-01A1, MSK’s Experimental Therapeutics Center, the LUNGevity Foundation, and the V Foundation. Wellspring Biosciences provided ARS853.


Commenting is disabled for this blog post.

Is there a trial right now open??

Dear Mariana, the treatment discussed in this blog post is still in the early stages of pre-clinical investigation and more work needs to be done before clinical trials can start. If you are interested in learning more about the trials we do have available for people with lung cancer, please visit or call our Physician Referral Service at 800-225-2225. Thank you for reaching out to us.

My sister was just (Nov 23, 2016) diagnosed with NSCLC adenocarcinoma left lower lobe, with KRAS mutation, have you started the trial for ARS853?

Hi Kate, we’re sorry to hear about your sister’s diagnosis. The compound discussed in this story is not yet being tested in clinical trials at MSK. If you sister would like to speak with someone here about other trials that might be right for her, she can call 800-525-2225 or go to for more information on making an appointment. Thank you for your comment, and best wishes to you.

Is there any update as to the potential timetable of this drug opening for a clinical trial?

Dear Jim, this research is still in the preclinical testing stage, and it’s too early to know when it may be available for trials to evaluate it in patients. Thank you for your comment.

I saw on TV 10/24 genetic breakthrough. My sister has EGFR Exon20 Insertion. She has not responded to chemo or immunotherapy and has just gone into hospice. Any trials or help?